Cetuximab has an inhibitory effect on cell motility in SCC-4 oral squamous cell carcinoma cell line

Cetuximab is a chimeric monoclonal antibody that acts as a competitive antagonist, by binding to EGFR. This cell signalling pathways regulates tumor progression. The oral squamous cell carcinoma undergoes to regional spreading and distant metastasis. This study aimed to evaluate the effect of treatm...

Full description

Saved in:

Bibliographic Details
Published in:	Cellular and Molecular Biology Vol. 63; no. 9; pp. 13 - 17
Main Authors:	Furtado, L M, Da Silveira, I C, Carneiro, A C D M, Zehuri, M M O N, Carboni, S S C M, Tavares-Murta, B M, Crema, V O
Format:	Journal Article
Language:	English
Published:	France 30-09-2017
Subjects:	Actin Cytoskeleton - drug effects Actin Cytoskeleton - pathology Antineoplastic Agents, Immunological - pharmacology Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Cell Line, Tumor Cell Movement - drug effects Cetuximab - pharmacology Humans Mouth Neoplasms - drug therapy Mouth Neoplasms - pathology Neoplasm Invasiveness - pathology Neoplasm Invasiveness - prevention & control SCC-4 Cell invasion Actin cytoskeleton Cetuximab Cell migration
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Cetuximab is a chimeric monoclonal antibody that acts as a competitive antagonist, by binding to EGFR. This cell signalling pathways regulates tumor progression. The oral squamous cell carcinoma undergoes to regional spreading and distant metastasis. This study aimed to evaluate the effect of treatment with Cetuximab on cell migration and invasion in OSCC cells, by using the SCC-4 cell line. Cell migration and cell invasion assay were performed and actin cytoskeleton of control and treated with Cetuximab cells were evaluated. Differences were considered significant when p<0.05.Cetuximab inhibited the migration of SCC-4 cells at three concentrations: 1 µg/mL, 50 µg/mL and 100 µg/mL (p<0.0001) in a dose-dependent manner. The number of SCC-4 treated cells with 1 μg/mL that migrated through the membrane was statistically different from 50 μg/mL (p<0.001) and 100 μg/mL (p<0.0001), and between 50 μg/mL and 100 μg/mL (p<0.01). Cetuximab 50 μg/mL inhibited cell invasion through the MatrigelTM compared with SCC-4 control cells (p<0.01). Cetuximab 50 μg/mL affected the organization of the actin cytoskeleton. Cetuximab has an inhibitory effect on actin cytoskeleton organization, cell migration and invasion, suggesting that Cetuximab treatment can be important to avoid oral squamous cell carcinoma metastasis.
ISSN:	0145-5680 1165-158X
DOI:	10.14715/cmb/2017.63.9.3